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Abstract: Although the presence of nodal disease is prognostic in 
thymic malignancy, the significance of the extent of nodal disease 
has yet to be defined. Lymph node dissection has not been routinely 
performed, and there is currently no node map defined for thymic 
malignancy. To establish a universal language for reporting as well as 
characterize the staging of this disease more accurately, an empiric 
node map is proposed here. This was developed using prior classifi-
cation systems, series reporting specifics of nodal involvement, ana-
tomical studies of lymphatic drainage, and preexisting node maps of 
the chest as defined by the International Association for the Study of 
Lung Cancer and the neck as defined by the American Academy of 
Otolaryngology—Head and Neck Surgery and the American Society 
for Head and Neck Surgery. The development of this node map 
was a joint effort by the International Thymic Malignancy Interest 
Group and the Thymic Domain of the IASLC Staging and Prognostic 
Factors Committee. It was reviewed and subsequently approved by 
the members of ITMIG. This map will be used as an adjunct to define 
node staging as part of a universal stage classification for thymic 
malignancy. As more data are gathered using definitions set forth by 
this node map, a revision may be undertaken in the future.
Key Words: Thymic malignancy, Thymoma, Thymic carcinoma, 
Thymic neuroendocrine tumor, Anterior mediastinal nodes, Thymic 
node map, Anterior mediastinal node map, ITMIG.
(J Thorac Oncol. 2014;9: S88–S96)
For many decades, little progress has been made in out-comes of patients with thymic malignancies. As an orphan 
disease, it has proven difficult to assemble a large series of 
patients to establish an evidence base. A further problem has 
been a lack of clear definitions of terms. This issue hampers 
communication between centers and the ability to compare 
and combine data.
The International Thymic Malignancies Interest Group 
(ITMIG) was created to provide infrastructure to overcome 
these hurdles. ITMIG conducted several international work-
shops and developed standard definitions of terms and poli-
cies that were overwhelmingly endorsed by the ITMIG 
membership. ITMIG has also partnered with the International 
Association for the Study of Lung Cancer (IASLC) to develop 
proposals for a validated stage classification system. To date, 
15 major stage classification systems have been proposed, 
with most being relatively empiric based on a small number of 
patients. ITMIG and IASLC have brought together the global 
community and amassed a database of more than 10,000 
patients to inform the stage classification proposals.
There is a need to develop a universally accepted defini-
tion of areas of nodal involvement from thymic malignancies. 
Unfortunately, the large database assembled for the stage clas-
sification project is retrospective, and details regarding which 
nodes were involved are vague. To gather data for a more 
accurate assessment, it is necessary to establish a consistent 
starting point, similar to the development of other standards 
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that ITMIG has undertaken in this disease. Therefore, ITMIG 
established a workgroup to accomplish this and combined this 
effort with the Thymic Domain of the IASLC Staging and 
Prognostic Factors Committee (TD-SPFC). This article is the 
result of this effort.
METHODS
Process for Development of Recommendations
An initial core workgroup was assembled to review 
existing literature that was relevant to a node classification 
system for thymic malignancies (David Chen, Faiz Bhora, and 
Frank Detterbeck). This included in broad terms, previously 
proposed classification systems, series reporting specifics of 
nodal involvement, existing maps for other spatially related 
tumors (i.e., lung, laryngotracheal, and oropharyngeal can-
cers), and anatomical studies of the lymphatic drainage of 
the mediastinum. Based on this review, the core workgroup 
formulated preliminary recommendations, which were further 
discussed at a meeting of the large diverse international group 
of specialists at the 2013 ITMIG annual meeting (Bethesda, 
MD, September 2013). The ensuing proposals were further 
refined by the TD-SPFC, which functioned as an extended 
workgroup (Hisao Asamura, Conrad Falkson, Pier Luigi 
Filosso, Giuseppe Giaccone, James Huang, Jhingook Kim, 
Kazuya Kondo, Marco Lucchi, Mirella Marino, Edith Marom, 
Andrew Nicholson, Meinoshin Okumura, Enrico Ruffini, and 
Paul van Schil). Funding for the TD-SPFC was provided by 
IASLC. Comments were also sought from the entire ITMIG 
membership, which represents the vast majority of investiga-
tors active in this disease, in keeping with an ITMIG process 
for the development and acceptance of proposed standards. 
This process also included eventual formal approval by the 
members of ITMIG for adoption going forward as the standard 
to follow. Because no data was available to analyze relative to 
the node map beyond what the TD-SPFC performed for T, N 
and M components of the proposed thymic stage classifica-
tion (reported elsewhere), Cancer Research And Biostatistics 
(CRAB) and the full IASLC SPFC committees and advisory 
boards encompassing all thoracic disease sites were only 
indirectly involved. Input was specifically sought out from 
the TNM committee of the Japan Lung Cancer Society (Jun 
Nakjima, Masaki Hara, Kazuya Kondo, Meinoshin Okumura, 
Yoshihiro Matsuno, Motoki Yano), because of the work that 
this group and others in Japan have done to investigate the 
impact of nodal involvement in thymic malignancies. After 
careful evaluation of all input, the final node classification 
system was defined as presented in this article.
Background
Existing thymic classification systems.
An official, universally accepted staging system has 
not been available for thymic epithelial tumors. Previously 
proposed thymic stage classification systems have been 
recently summarized.1 The most widely accepted system is 
the Masaoka classification, initially established in 1981 and 
modified in 1994 by Koga et al.2 The four-tiered Masaoka-
Koga system stratifies stages I to IVA based on tumor stage/
extent of invasion, whereas stage IVB is reserved for nodal 
and distant metastasis combined; this was endorsed by the 
International Thymic Malignancy Interest Group (ITMIG) 
in 2011.3,4 The Masaoka-Koga system seems to be a good 
predictor of prognosis for thymoma, the most common thy-
mic epithelial tumor; however, it may not be as accurate for 
staging thymic carcinoma and neuroendocrine tumors of the 
thymus.5,6 Despite sharing anatomical origin, thymomas are 
clinicopathologically distinct from thymic carcinomas and 
neuroendocrine tumors of the thymus; nodal metastasis is rare 
in the former, more common in the latter.
Four thymic classification systems have defined N sub-
groups, summarized in Table 1. The Yamakawa/Masaoka7 and 
National Cancer Center Hospital of Japan8 systems are the 
same with respect to definition of the N subgroups (they dif-
fer in the T definitions and the stage groupings). The World 
Health Organization Consensus Committee9 and the Istituto 
Nazionale Tumori10 systems are also almost identical to one 
another. Overall, the primary difference in these systems is 
that the more recent ones specify specific neck nodes as N3 
instead of simply grouping all extrathoracic nodes together. 
Specific definitions of anatomic boundaries of the nodal 
regions were not provided in these manuscripts.
Nodal metastasis patterns of thymic malignancies.
A review of 1320 thymic epithelial tumors by Kondo6 
revealed a 3.2% incidence of lymphogenous and/or distant metas-
tasis (stage IVB) in patients with thymoma, and a 33% incidence of 
such metastases in thymic carcinoma patients. He also calculated 
significant 5-year survival differences between stages IVA and IVB 
(p = 0.019 for overall, p = 0.023 tumor-specific 5-year survival). 
TABLE 1.  Thymic Malignancy Classification Systems
Yamakawa NCCHJ WHO INT
N0 No lymph node metastasis No lymph node metastasis No lymph node metastasis No lymph node metastasis
N1 Metastasis to anterior 
mediastinal lymph nodes
Metastasis to anterior 
mediastinal lymph nodes
Metastasis to anterior mediastinal 
lymph nodes
Metastasis to anterior mediastinal lymph 
nodes
N2 Metastasis to intrathoracic 
lymph nodes except anterior 
mediastinal lymph nodes
Metastasis to intrathoracic 
lymph nodes excluding 
anterior mediastinal 
lymph nodes
Metastasis to other intrathoracic 
lymph nodes excluding anterior 
mediastinal lymph nodes
Metastasis to intrathoracic lymph nodes 
other than anterior mediastinal lymph 
nodes
N3 Metastasis to extrathoracic 
lymph nodes
Metastasis to extrathoracic 
lymph nodes
Metastasis to scalene and/or 
supraclavicular lymph nodes
Metastasis to prescalene or supraclavicular 
lymph nodes
NCCHJ, National Cancer Center Hospital of Japan; WHO, World Health Organization; INT, Istituto Nazionale Tumori.
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This indicates that the presence of nodal or distant metastasis 
influences prognosis, warranting further investigation.
Anterior mediastinal lymph nodes seem to be the pri-
mary drainage basin for thymic epithelial tumors. This has 
been determined based on frequency and pattern of metas-
tasis in addition to anatomical location (however, thymic 
carcinomas may exhibit skip metastases). If there is nodal 
involvement, these are located in the anterior mediastinum in 
approximately 90% in thymomas, 70% in thymic carcinomas, 
and 90% in neuroendocrine tumors of the thymus.5
Kondo et al also subclassified stage IVB into 
IVBi (TanyN1M0), IVBii (TanyN2-3M0), and IVBiii 
(TanyNanyM1), but found no differences in 5-year survival 
(p = 0.24 between IVA and IVBi, p = 0.25 between IVBi and 
IVBii, and p = 0.52 between IVBii and IVBiii).6 The small 
size of these subgroups (IVBi n = 25, IVBii n= 25, and IVBiii 
n = 26) undermines the ability to assess statistical signifi-
cance; however, there was a trend toward improved survival 
for the N1 group compared with the N2/N3 group. In addition, 
there may have been unresectable stage IVB cases that were 
not included in the database provided by the member surgeons 
of the Japanese Association for Chest Surgery. Although the 
mere presence of nodal disease has prognostic influence, the 
prognostic effect of characteristics of metastasis such as loca-
tion, number of nodes, number of stations, presence of angio-
lymphatic invasion, perineural involvement, and extracapsular 
involvement remains to be determined.
Anatomical studies of mediastinal lymphatics.
An extensive literature search reveals that there is no 
established lymph node nomenclature delineating the anterior 
mediastinal nodes other than the N staging systems presented 
in Table 1.7–10 There were, however, several sources that were 
helpful in identifying mediastinal nodes and drainage patterns:
1.  Caplan11: Classification of the human mediastinum 
based upon a longitudinal series of 984 autopsies over 
17 years. Injection of hydrogen peroxide was used to 
delineate lymphatic drainage in cadaveric subjects. Of 
particular note, the anterior mediastinum was deter-
mined to contain five major node groups on the right 
and six major node groups on the left: right and left 
superior internal thoracic, right and left brachioce-
phalic, right superior phrenic (superior precaval), left 
superior phrenic (preaortic), right inferior phrenic (infe-
rior precaval), left inferior phrenic (prepericardial), azy-
gos arch, aortic arch/pulmonary artery, and left superior 
vagal/preaortic subclavian-carotid chain.
2.  Murakami et al12: Classification of bronchomediasti-
nal collecting vessels based on cadaveric dissection of 
eight subjects. The authors observed consistent lym-
phatic trunks, or large collecting vessels, on the right in 
an anterior and posterior pathway, and variable trunks 
on the left in a superior and inferior pathway with three 
consistent contributory node groups. In particular, the 
divisions on the right included the right brachiocephalic 
and anterior/posterior mediastinal trunks, whereas the 
divisions on the left included the uppermost paratra-
cheal nodes, anterior mediastinal nodes (surrounding 
the phrenic nerve anterior and inferior to the aortic 
arch), and the left tracheobronchial nodes. They also 
observed a prominent communicating vessel between 
the right and left systems situated anterior to the tra-
chea and above the aortic arch; it was often associated 
with the brachiocephalic angle nodes. Altogether, the 
results suggested prominence of the following nodal 
groups: brachiocephalic angle, right/left venous angles 
(jugulo-subclavian junction), phrenic, paratracheal, and 
tracheobronchial.
3.  Gregoire et al13: Description of anatomic and func-
tional mediastinal drainage pathways as it relates to 
clinical target volumes for radiation therapy in cancer 
treatment. The thorax is divided into four major com-
partments: parasternal, brachiocephalic, intertracheo-
bronchial, and posterior mediastinal. The parasternal 
area is defined craniocaudally by the sternoclavicular 
joints and the xiphoid, and in an anterior/posterior 
plane by the deep surface of the sternum to the trans-
versus thoracis, respectively. The brachiocephalic area 
includes the anterior mediastinal fat and the area ante-
rior to the great vessels; craniocaudally, its boundaries 
are the clavicle and T6, and its lateral boundaries are 
the right and left mediastinal pleura. In addition, the 
entire thorax was functionally classified into an ante-
rior, central, and posterior stream. The anterior stream 
includes the parasternal and brachiocephalic compart-
ments and unites with the central (primarily tracheo-
bronchial) stream in the superior mediastinum to form 
the common bronchomediastinal trunks.
Related classifications.
In the IASLC lung cancer node map proposal,14 the 
workgroup notably identified that lymph node drainage in 
the superior mediastinum converges over the right paratra-
cheal area and extends across the midline toward the left. 
Appropriately, the demarcation between right and left in terms 
of levels 2 and 4 needed not lie over the midline trachea, but 
instead to the left lateral border of the trachea. A recent retro-
spective review by Park et al15 corroborates this—metastasis 
was mainly found in the right paratracheal nodes, and they 
recommended dissection of 10 or more lymph nodes in the 
anterior mediastinum and the right paratracheal area in thymic 
carcinoma.
The American Academy of Otolaryngology—Head and 
Neck Surgery/American Society for Head and Neck Surgery 
(AAO-HNS/ASHNS) node map16 (established in 1991, updated 
in 2002) provides a correlate for neck lymph nodes as it relates 
to superior mediastinal tumors. The anterior lower neck is of 
particular interest as selective neck dissection of this region is 
indicated for thyroid cancer and cervical esophageal/tracheal 
cancer. These lymph nodes consist of paratracheal, precricoid 
(Delphian), and perithyroidal/recurrent laryngeal nodes.
RESULTS
The node map that was developed is a functional demar-
cation of mediastinal regions that incorporates retrospective 
data, preexisting node classifications in the IASLC map and 
the AAO-HNS/ASHNS map, and prominent nodes defined 
by prior studies.11–13 Retrospective data and current N staging 
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systems7–10 describe anterior mediastinal nodes as the primary 
drainage pathway and intrathoracic nodes excluding the ante-
rior mediastinum as the secondary drainage pathway.
Two major regions are defined by the map: anterior 
and deep. The most logical method of describing regions is 
based on the boundaries that define the peripheral extent of 
dissection in all axes; this reflects the method used for thy-
mic dissection in which the specimen is removed en bloc. It 
is sometimes challenging to orient visceral anatomical land-
marks relative to the thymus during dissection in vivo, and 
it is even more difficult to do so once the specimen has been 
explanted from the patient. Given that prognostic importance 
to particular regions has not been demonstrated, it seems more 
practical not to complicate the system by subdividing nodes 
beyond what is encompassed by an extensive en bloc resection 
as described. There may be more evidence to perform dedi-
cated lymph node dissections15 in thymic carcinoma, but such 
nodes can be defined within these proposed regions. Similarly, 
the issue of laterality in node metastasis is not well defined. 
As aforementioned, there is data that suggest prominence of 
right paratracheal nodes in node-positive cases. Aside from 
that, however, there is no evidence to support the significance 
of laterality in other node stations.
Prominent nodes defined uniformly by Caplan,11 
Murakami et al,12 and Gregoire et al13 are included and distrib-
uted to the appropriate regions in this map ([1] low cervical/
sternal notch, [2] venous angle: left and right, [3] brachioce-
phalic angle, [4] tracheobronchial: left and right, [5] paraaor-
tic, [6] subaortic, [7] superior phrenic: left and right (preaortic/
precaval), and [8] inferior phrenic: left and right).
The anterior region (N1) (Table 2, Figures 1–6) encom-
passes the space surrounding the thymus that is anterior to 
the pericardium and great vessels, extending from the hyoid 
bone superiorly to the diaphragm inferiorly and between the 
mediastinal pleura. The anterior region extends from the back 
of the sternum anteriorly; the posterior border is the pericar-
dium in the middle and the level of the phrenic nerves in the 
lateral aspects of the mediastinum. These boundaries reflect 
the conventional dissection performed in extended thymec-
tomy (dissection of contiguous left and right mediastinal 
pleura, mediastinal, and pericardiophrenic fatty tissues and 
dissection of paraaortic [IASLC level 6] nodes in addition 
to complete removal of thymus).17 The computed tomogra-
phy images in the figures demonstrate the posterior floor of 
the anterior region in several representative sections. In those 
anatomical sections not represented by these figures, radiolo-
gists should follow the guideline of demarcating the regions 
by the peripheral extent of conventional surgical dissection as 
previously mentioned.
This region includes anterior mediastinal nodes (peri-
thymic, prevascular, paraaortic, and supradiaphragmatic 
nodes) and anterior cervical nodes (as conventionally defined 
by level 6 of the AAO-HNS/ASHNS classification). The 
term perithymic nodes is meant for lymph nodes immedi-
ately adjacent to the thymus that are not captured in one of 
the other categories (which were developed with lung can-
cer in mind). In the area of the great vessels, the posterior 
boundary of this region includes paraaortic nodes (IASLC 
level 6) but not aortopulmonary window nodes (IASLC level 
5). Therefore, the posterior border of the anterior region is 
defined as the anterior border of the aortopulmonary window 
(Figures 4 and 5). The internal mammary nodes are excluded 
from this region (and allocated instead to the deep region) 
because they are rarely dissected in practice and there is no 
TABLE 2.  Anterior Region (N1) (Anterior Mediastinal and Anterior Cervical Nodes)
Region Boundaries Node Groups14, 16 Node Group Boundaries 
Sup: Hyoid Bone 
Lat (Neck): Medial Border of 
Carotid Sheaths 
Lat (Chest): Mediastinal Pleura 
Ant: Sternum 
Post (Medially): Great Vessels, 
Pericardium 
Post (Laterally): Phrenic Nerve 
Inf: Xiphoid, diaphragm 
Low Ant Cervical: Pretracheal, 
Paratracheal, Peri-thyroid, 
Precricoid/Delphian 
(AAO-HNS / ASHNS Level 6 / 
IASLC Level 1) 
Sup: inferior border of cricoid 
Lat: common carotid arteries 
Inf: superior border of manubrium 
Peri-Thymic Proximity to thymus 
Prevascular  
(IASLC Level 3a) 
Sup: apex of chest 
Ant: posterior sternum 
Post: anterior SVC 
Inf: carina 
Paraaortic, Ascending Aorta, 
Superior Phrenics  
(IASLC Level 6) 
Sup: line tangential to sup border of aortic arch 
Inf: inf border of aortic arch 
Supradiaphragmatic / Inferior 
Phrenics / Pericardial (along 
inferior poles of thymus) 
Sup: inf border of aortic arch 
Ant: post sternum  
Post: phrenic nerve (laterally) or pericardium 
(medially) 
Inf: diaphragm 
Region and node group boundaries adapted directly from definitions established by AAO-HNS, ASHNS, and IASLC.
AAO-HNS, American Academy of Otolaryngology—Head and Neck Surgery; ASHNS, American Society for Head and Neck Surgery; 
IASLC, International Association for the Study of Lung Cancer; sup, superior; ant, anterior; inf, inferior; lat, lateral; post, posterior; SVC, 
superior vena cava.
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FIGURE 1.  Mediastinum, sagittal section. Anterior region (blue) and deep region (purple). Tr, trachea; E, esophagus; LPA, left 
pulmonary artery; A, aorta; D, diaphragm.
FIGURE 2.  Thoracic inlet, axial section. Anterior region (blue) and deep region (purple). CCA, common carotid  
artery; IJV, internal jugular vein; Tr, trachea; Clav, clavicle; E, esophagus.
FIGURE 3.  Paraaortic level, axial section. Anterior region (blue) and deep region (purple). SVC, superior vena cava;  
E, esophagus; Tr, trachea.
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FIGURE 4.  Aortopulmonary window level, axial section. Anterior region (blue) and deep region (purple). Note: deep region 
includes aortopulmonary window nodes. AA, ascending aorta; DA, descending aorta; LPA, left pulmonary artery; SVC, superior 
vena cava; Az, azygos vein; RB, right main bronchus; LB, left main bronchus.
FIGURE 5.  Carina level, axial section. Anterior region (blue) and deep region (purple). Note: deep region includes aortopulmo-
nary window nodes. AA, ascending aorta; DA, descending aorta; PT, pulmonary trunk; LPA, left pulmonary artery; RPA,  
right pulmonary artery; SVC, superior vena cava; LSPV, left superior pulmonary vein; BR, bronchus; E, esophagus.
FIGURE 6.  Diaphragm level, axial section. Anterior region (blue) and deep region (purple). RV, right ventricle; LV, left ventricle; 
IVC, inferior vena cava; DA, descending aorta; E, esophagus.
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evidence to support the significance of disease in this area in 
thymic malignancy.
The deep region (N2) (Table 3, Figures 1–6) describes 
the space distant to the anterior region within the mediastinum. 
It is situated posterior to the anterior mediastinum, anterior to 
the esophagus, and among the pulmonary hila; it extends into 
the neck on either side of the anterior cervical nodes.
This region includes tracheobronchial and aortopul-
monary window nodes (as defined by the IASLC node map), 
internal mammary nodes, deep cervical nodes, and supracla-
vicular nodes (as defined by the AAO-HNS map). The aor-
topulmonary window nodes are included in the deep region. 
These nodes are posterior to the phrenic nerve and not always 
included in the field of dissection; also, there is no data to sup-
port specific prognostic significance of nodal disease in this 
area. Also, although internal mammary nodes are anatomi-
cally separate from the rest of the deep region, they are rarely 
positive for nodal disease and thus, they can be regarded as 
pathologically “distant.”
All nodes not defined by the anterior and deep regions 
are considered to be extrathoracic metastases (M1). These 
may include nodal disease in the axillary, retroperitoneal, or 
inguinal lymph node regions.
DISCUSSION
Lymph node involvement carries prognostic signifi-
cance. However, definition of the importance of the location 
or extent of nodal involvement is not possible at this time. 
There is insufficient data; moreover, there are numerous pro-
posed TNM staging systems that describe N1, N2, and N3 in 
generic terms that are open to interpretation. The development 
of worldwide standards through the efforts of ITMIG, the col-
lection of prospective data in the ITMIG database, and the 
anticipated implementation of an official uniform stage clas-
sification system provides an opportunity to gather the data 
needed to assess the impact of details of node involvement. A 
prerequisite is the availability of a method to classify nodes in 
a consistent manner. We can only advance our knowledge as 
much as our existing framework allows.
The division of the mediastinum into an anterior and 
deep region is an empiric method of organizing these named 
nodes into a logical construct given our current data. It satis-
fies the need for a simple system to facilitate widespread adop-
tion, and it builds on node classifications that are familiar to 
the community (namely, the IASLC and AAO-HNS/ASHNS 
node classifications) and anatomical patterns of mediastinal 
drainage. Consideration was given to defining the map based 
on discrete node stations, but a region-based system seems to 
be more appropriate to reflect the method of en bloc dissection 
in current practice and make this map globally applicable. By 
defining node areas both anatomically and on CT images, we 
may improve both clinical and pathological staging. Involved 
nodes should be classified as in either the “anterior region” 
or “deep region” according to the boundaries described; if 
possible, the specific location of the node should be recorded 
as well. Any invasion of nodes via direct extension should 
be considered nodal disease; this is similarly practiced with 
regard to N staging in lung cancer.18
The ITMIG standard policies for surgeons encourage 
removal of anterior mediastinal nodes at the time of resec-
tion for tumors that seem localized to the thymus.19 The clas-
sification outlined here fits this policy, because the generally 
accepted definition of an extended thymectomy includes 
nodes of the anterior region. Pathologists should examine all 
submitted lymph nodes and record whether they are positive 
or negative for tumor. In addition, the total number of nodes 
sampled from each region should be recorded and included in 
the prospective database. For thymomas with adjacent organ 
involvement (Masaoka stage III or IVA undergoing curative-
intent resection), it is recommended that anterior mediasti-
nal lymph nodes be routinely removed and submitted, and a 
systematic sampling of intrathoracic sites is encouraged (i.e., 
nodes corresponding to the deep region). For thymic carci-
noma, a routine systematic removal and submission of nodes 
in both the anterior and deep regions are recommended.
We accept that development of this mediastinal node 
map is essentially empiric. However, the process of estab-
lishing this lymph node map was similar to that utilized for 
the IASLC lung cancer lymph node map.14 They reconciled 
discrepancies in the definitions among various node classi-
fications and established a universal map for application in 
future investigations. Cadaveric studies (as described above) 
delineating anatomical and functional lymph node drainage 
pathways via injection were referenced. Endorsement was 
achieved using a multidisciplinary workgroup within an inter-
national committee. It should be pointed out that in most tumor 
types, an initial node classification was developed empirically, 
and data accumulated later regarding the prognostic impact.
Much work remains to be done to clarify and improve 
thymic epithelial tumor staging. A universally adopted nodal 
map is needed to collect data in a consistent manner. Through 
the process of building on existing maps, knowledge of 
mediastinal drainage, broad input from all major groups and 
organizations active in this area, and involvement of ITMIG 
and the IASLC Staging and Prognostics Factors Committee, 
consensus has been developed for a simple two-region node 
map. This will set the stage to gather more consistent infor-
mation and potentially contribute to future stage classification 
systems.
APPENDICES
Appendix 1:  IASLC Staging and Prognostic  
Factors Committee
Peter Goldstraw, Past Chair, Royal Brompton Hospital and Imperial 
College, London, United Kingdom; Ramón Rami-Porta, Chair, Hospital 
UniversitariMutuaTerrassa, Terrassa, Spain; Hisao Asamura, Chair Elect, 
National Cancer Center, Tokyo, Japan; David Ball, Peter MacCallum Cancer 
Centre, Melbourne, Australia; David Beer, University of Michigan, Ann 
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Valerie Rusch, Memorial Sloan-Kettering Cancer Center, New York, NY, 
USA; NagahiroSaijo, National Cancer Center Hospital East, Chiba, Japan; 
Paul Van Schil, Antwerp University Hospital, Edegem (Antwerp), Belgium; 
Jean-Paul Sculier, Institut Jules Bordet, Brussels, Belgium; Lynn Shemanski, 
Cancer Research And Biostatistics, Seattle, WA, USA; Kelly Stratton, Cancer 
Research And Biostatistics, Seattle, WA, USA; Kenji Suzuki, Juntendo 
University, Tokyo, Japan; Yuji Tachimori, National Cancer Center, Tokyo, 
Japan; Charles F. Thomas Jr, Mayo Clinic, Rochester, MN, USA; William 
Travis, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Ming 
S. Tsao, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada; 
Andrew Turrisi, Sinai Grace Hospital, Detroit, MI, USA; Johan Vansteenkiste, 
University Hospitals KU Leuven, Leuven, Belgium; Hirokazu Watanabe, 
National Cancer Center Hospital, Tokyo, Japan; Yi-Long Wu, Guangdong 
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Appendix 2: Advisory Board of the 
IASLC Thymic Malignancies Domain
Conrad Falkson, Queen’s University, Ontario, Canada; Pier Luigi Filosso, 
University of Torino, Italy; Giuseppe Giaccone, Georgetown University, 
Washington, DC, USA; Kazuya Kondo, University of Tokushima, Tokushima, 
Japan; Marco Lucchi, University of Pisa, Pisa, Italy; Meinoshin Okumura, 
Osaka University, Osaka, Japan.
Appendix 3: Advisory Board of the IASLC  
Mesothelioma Domain
Paul Baas, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 
Jeremy Erasmus, MD Anderson Cancer Center, Houston, TX, USA; Seiki 
TABLE 3.  Deep Region (N2) (Middle Mediastinal and Deep Cervical Nodes)
Region Boundaries Node Groups14, 16 Node Group Boundaries
Sup: Level of lower border of 
cricoid cartilage
Anteromedial (Neck): Lateral 
Border of Sternohyoid, Medial 
Border of Carotid Sheath
Posterolateral (Neck): Anterior 
Border of Trapezius
Ant (Chest): Aortic Arch, 
Aortopulmonary Window –
Ant Border of SVC
Post (Chest): Esophagus
Lat (Chest): Pulmonary Hila 
Inf: Diaphragm
Lower Jugular 
(AAO-HNS / ASHNS Level 4)
Sup: Level of lower border of cricoid cartilage
Anteromedial: lat border of sternohyoid
Posterolateral: lat border of sternocleidomastoid
Inf: clavicle
Supraclavicular/Venous Angle: 
Confluence of Internal Jugular 
& Subclavian Vein 
(AAO-HNS / ASHNS Level 5b)
Sup: Level of lower border of cricoid cartilage
Anteromedial: post border of sternocleidomastoid
Posterolateral: ant border of trapezius
Inf: clavicle
Internal Mammary nodes Proximity to internal mammary arteries
Upper Paratracheal
(IASLC Level 2)
Sup: sup border of manubrium, apices of lungs
Inf: intersection of lower border of innominate vein 
with trachea; sup border of aortic arch
Lower Paratracheal 
(IASLC Level 4)
Sup: intersection of lower border of innominate 
vein with trachea; sup border of aortic arch
Inf: lower border of azygos vein, sup border of left 
main pulmonary artery
Subaortic / Aortopulmonary 
Window 
(IASLC Level 5)
Sup: inf border of aortic arch
Inf: sup border of left main pulmonary artery
Subcarinal 
(IASLC Level 7)
Sup: carina
Inf: upper border of lower lobe bronchus on the 
left; lower border of the bronchus intermedius 
on the right
Hilar
(IASLC Level 10)
Sup: lower rim of azygos vein on right, upper rim 
of pulmonary artery on left
Inf: interlobar region bilaterally
Region and node group boundaries adapted directly from definitions established by AAO-HNS, ASHNS, and IASLC.
AAO-HNS, American Academy of Otolaryngology—Head and Neck Surgery; ASHNS, American Society for Head and Neck Surgery; 
IASLC, International Association for the Study of Lung Cancer; sup, superior; ant, anterior; inf, inferior; lat, lateral; post, posterior; SVC, superior 
vena cava.
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Esophageal Cancer Domain
Eugene Blackstone, Cleveland Clinic, OH, USA. 
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